Aripiprazole Sandoz

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
27-02-2024

Ingredient activ:

aripiprazole

Disponibil de la:

Sandoz GmbH

Codul ATC:

N05AX12

INN (nume internaţional):

aripiprazole

Grupul Terapeutică:

Psycholeptics

Zonă Terapeutică:

Schizophrenia; Bipolar Disorder

Indicații terapeutice:

Aripiprazole Sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole Sandoz is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Sandoz is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,

Rezumat produs:

Revision: 9

Statutul autorizaţiei:

Authorised

Data de autorizare:

2015-08-20

Prospect

                                54
B. PACKAGE LEAFLET
55 PACKAGE LEAFLET: INFORMATION FOR THE USER
ARIPIPRAZOLE SANDOZ 5 MG TABLETS
ARIPIPRAZOLE SANDOZ 10 MG TABLETS
ARIPIPRAZOLE SANDOZ 15 MG TABLETS
ARIPIPRAZOLE SANDOZ 20 MG TABLETS
ARIPIPRAZOLE SANDOZ 30 MG TABLETS
aripiprazole
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even
if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Aripiprazole Sandoz tablets are and what they are used for
2.
What you need to know before you take Aripiprazole Sandoz tablets
3.
How to take Aripiprazole Sandoz tablets
4.
Possible side effects
5.
How to store Aripiprazole Sandoz tablets
6.
Contents of the pack and other information
1.
WHAT ARIPIPRAZOLE SANDOZ IS AND WHAT IT IS USED FOR
Aripiprazole Sandoz contains the active substance aripiprazole and
belongs to a group of medicines called
antipsychotics. It is used to treat adults and adolescents aged 15
years and older who suffer from a disease
characterised by symptoms such as hearing, seeing or sensing things
which are not there, suspiciousness,
mistaken beliefs, incoherent speech and behaviour and emotional
flatness. People with this condition may
also feel depressed, guilty, anxious or tense.
Aripiprazole Sandoz is used to treat adults and adolescents aged 13
years and older who suffer from a
condition with symptoms such as feeling "high", having excessive
amounts of energy, needing much less
sleep than usual, talking very quickly with racing ideas and sometimes
severe irritability. In adults it also
prevents this condition from returning in patients who have responded
to the treatment w
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Aripiprazole Sandoz 5 mg tablets
Aripiprazole Sandoz 10 mg tablets
Aripiprazole Sandoz 15 mg tablets
Aripiprazole Sandoz 20 mg tablets
Aripiprazole Sandoz 30 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Aripiprazole Sandoz 5 mg tablets
Each tablet contains 5 mg of aripiprazole.
Excipient with known effect
67.47 mg lactose (as monohydrate) per tablet.
Aripiprazole Sandoz 10 mg tablets
Each tablet contains 10 mg of aripiprazole.
Excipient with known effect
62.67 mg lactose (as monohydrate) per tablet.
Aripiprazole Sandoz 15 mg tablets
_ _
Each tablet contains 15 mg of aripiprazole.
Excipient with known effect
92.86 mg lactose (as monohydrate) per tablet.
Aripiprazole Sandoz 20 mg tablets
Each tablet contains 20 mg of aripiprazole.
Excipient with known effect
125.72 mg lactose (as monohydrate) per tablet.
Aripiprazole Sandoz 30 mg tablets
Each tablet contains 30 mg of aripiprazole.
Excipient with known effect
186.68 mg lactose (as monohydrate) per tablet.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Aripiprazole Sandoz 5 mg tablets
3
Blue coloured, mottled, round shaped tablet, with an approximate
diameter of 6.0 mm, debossed with “SZ”
on one side and “444” on the other side.
Aripiprazole Sandoz 10 mg tablets
Pink coloured, mottled, round shaped tablet, with an approximate
diameter of 6.0 mm, debossed with “SZ”
on one side and “446” on the other side.
Aripiprazole Sandoz 15 mg tablets
Yellow coloured, mottled, round shaped tablet, with an approximate
diameter of 7.0 mm, debossed with
“SZ” on one side and “447” on the other side.
Aripiprazole Sandoz 20 mg tablets
White coloured, round shaped tablet, with an approximate diameter of
7.8 mm, debossed with “SZ” on one
side and “448” on the other side.
_ _
_ _
Aripiprazole Sandoz 30 mg tablets
Pink coloured, mottled, round shaped tablet, with an approximate
diameter of 9.0 mm, debossed with “SZ”
on one side and 
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului bulgară 27-02-2024
Raport public de evaluare Raport public de evaluare bulgară 25-09-2015
Prospect Prospect spaniolă 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului spaniolă 27-02-2024
Raport public de evaluare Raport public de evaluare spaniolă 25-09-2015
Prospect Prospect cehă 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului cehă 27-02-2024
Raport public de evaluare Raport public de evaluare cehă 25-09-2015
Prospect Prospect daneză 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului daneză 27-02-2024
Raport public de evaluare Raport public de evaluare daneză 25-09-2015
Prospect Prospect germană 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului germană 27-02-2024
Raport public de evaluare Raport public de evaluare germană 25-09-2015
Prospect Prospect estoniană 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului estoniană 27-02-2024
Raport public de evaluare Raport public de evaluare estoniană 25-09-2015
Prospect Prospect greacă 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului greacă 27-02-2024
Raport public de evaluare Raport public de evaluare greacă 25-09-2015
Prospect Prospect franceză 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului franceză 27-02-2024
Raport public de evaluare Raport public de evaluare franceză 25-09-2015
Prospect Prospect italiană 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului italiană 27-02-2024
Raport public de evaluare Raport public de evaluare italiană 25-09-2015
Prospect Prospect letonă 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului letonă 27-02-2024
Raport public de evaluare Raport public de evaluare letonă 25-09-2015
Prospect Prospect lituaniană 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului lituaniană 27-02-2024
Raport public de evaluare Raport public de evaluare lituaniană 25-09-2015
Prospect Prospect maghiară 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului maghiară 27-02-2024
Raport public de evaluare Raport public de evaluare maghiară 25-09-2015
Prospect Prospect malteză 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului malteză 27-02-2024
Raport public de evaluare Raport public de evaluare malteză 25-09-2015
Prospect Prospect olandeză 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului olandeză 27-02-2024
Raport public de evaluare Raport public de evaluare olandeză 25-09-2015
Prospect Prospect poloneză 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului poloneză 27-02-2024
Raport public de evaluare Raport public de evaluare poloneză 25-09-2015
Prospect Prospect portugheză 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului portugheză 27-02-2024
Raport public de evaluare Raport public de evaluare portugheză 25-09-2015
Prospect Prospect română 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului română 27-02-2024
Raport public de evaluare Raport public de evaluare română 25-09-2015
Prospect Prospect slovacă 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului slovacă 27-02-2024
Raport public de evaluare Raport public de evaluare slovacă 25-09-2015
Prospect Prospect slovenă 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului slovenă 27-02-2024
Raport public de evaluare Raport public de evaluare slovenă 25-09-2015
Prospect Prospect finlandeză 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului finlandeză 27-02-2024
Raport public de evaluare Raport public de evaluare finlandeză 25-09-2015
Prospect Prospect suedeză 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului suedeză 27-02-2024
Raport public de evaluare Raport public de evaluare suedeză 25-09-2015
Prospect Prospect norvegiană 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului norvegiană 27-02-2024
Prospect Prospect islandeză 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului islandeză 27-02-2024
Prospect Prospect croată 27-02-2024
Caracteristicilor produsului Caracteristicilor produsului croată 27-02-2024
Raport public de evaluare Raport public de evaluare croată 25-09-2015

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor